journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/30446406/pneumonectomy-in-stage-iiia-n2-nsclc-should-it-be-considered-after-neoadjuvant-chemotherapy
#1
Monica Casiraghi, Juliana Guarize, Alberto Sandri, Patrick Maisonneuve, Daniela Brambilla, Rosalia Romano, Domenico Galetta, Francesco Petrella, Roberto Gasparri, Cesare Gridelli, Filippo De Marinis, Lorenzo Spaggiari
BACKGROUND: Owing to the expected poor long-term outcomes and high postoperative morbidity and mortality, patients with stage IIIA-N2 tumors candidate to pneumonectomy (PN) are usually excluded from surgery. This study aims to analyze the outcome of patients who underwent PN to prove its safety and feasibility. PATIENTS AND METHODS: We retrospectively analyzed data from 233 patients who underwent PN for N2 non-small-cell lung cancer (NSCLC) between 1998 and 2015...
October 24, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30442523/natural-disease-history-outcomes-and-co-mutations-in-a-series-of-patients-with-braf-mutated-non-small-cell-lung-cancer
#2
Nathaniel J Myall, Solomon Henry, Douglas Wood, Joel W Neal, Summer S Han, Sukhmani K Padda, Heather A Wakelee
BACKGROUND: BRAF mutations occur in 1% to 4% of non-small-cell lung cancer (NSCLC) cases. Previous retrospective studies have reported similar outcomes for BRAF-mutated NSCLC as compared with wild-type tumors without a known driver mutation or tumors harboring other mutations. However, select cases of prolonged survival have also been described, and thus, the natural history of BRAF-mutated NSCLC remains an area of ongoing study. The aim of this series was to describe the natural history, clinical outcomes, and occurrence of co-mutations in patients with BRAF-mutated NSCLC...
October 23, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30442524/association-between-immune-related-adverse-events-and-efficacy-of-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer
#3
Mathieu Grangeon, Pascale Tomasini, Solene Chaleat, Arnaud Jeanson, Maxime Souquet-Bressand, Nataliya Khobta, Julien Bermudez, Youssef Trigui, Laurent Greillier, Marilyne Blanchon, Mohamed Boucekine, Celine Mascaux, Fabrice Barlesi
BACKGROUND: Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non-small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs). The incidence, diagnosis, and treatment of IRAEs are quite acknowledged; however, the link between IRAEs and the efficacy of ICIs requires further clarification. The objectives of this study were to assess the association between IRAEs incidence and severity and ICIs efficacy in patients with advanced NSCLC...
October 11, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30414783/lace-bio-validation-of-predictive-and-or-prognostic-immunohistochemistry-histochemistry-based-biomarkers-in-resected-non-small-cell-lung-cancer
#4
Lesley Seymour, Gwénaël Le Teuff, Elisabeth Brambilla, Frances A Shepherd, Jean-Charles Soria, Robert Kratzke, Stephen Graziano, Jean-Yves Douillard, Rafael Rosell, Anthony Reiman, Benjamin Lacas, Beranger Lueza, Sarit Aviel-Ronen, Anne McLeer, Thierry Le Chevalier, Robert Pirker, Martin Filipits, Ariane Dunant, Jean-Pierre Pignon, Ming-Sound Tsao
BACKGROUND: Complete resection of non-small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. MATERIALS AND METHODS: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633)...
October 11, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30391211/molecular-diagnostic-assays-and-clinicopathologic-implications-of-met-exon-14-skipping-mutation-in-non-small-cell-lung-cancer
#5
Eun Kyung Kim, Kyung A Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
BACKGROUND: Recent studies revealed MET exon 14 skipping (METex14) as a biomarker that predicts the response to MET inhibitors in non-small-cell lung cancer (NSCLC). However, METex14 genomic alterations exhibit a highly diverse sequence composition, posing a challenge for clinical diagnostic testing. This study aimed to find a reasonable diagnostic assay for METex14 and identify its clinicopathologic implications. MATERIALS AND METHODS: We performed a comprehensive analysis of METex14 in 414 EGFR/KRAS/ALK/ROS1-negative (quadruple negative) surgically resected NSCLCs...
October 11, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30425022/association-of-tumor-mutational-burden-with-dna-repair-mutations-and-response-to-anti-pd-1-pd-l1-therapy-in-non-small-cell-lung-cancer
#6
Young Kwang Chae, Andrew A Davis, Kirtee Raparia, Sarita Agte, Alan Pan, Nisha Mohindra, Victoria Villaflor, Francis Giles
PURPOSE: To examine clinical predictors of tumor mutational burden (TMB), to explore the association between TMB and DNA repair mutations, and to analyze TMB as a biomarker for response to immune checkpoint blockade in non-small-cell lung cancer. PATIENTS AND METHODS: TMB scores were determined retrospectively for 72 consecutive patients at our institution with next-generation sequencing comprehensive genomic profiling testing by Foundation Medicine. TMB scores were correlated with a number of clinical variables and presence of DNA repair mutations...
September 25, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30343004/local-consolidation-therapy-lct-after-first-line-tyrosine-kinase-inhibitor-tki-for-patients-with-egfr-mutant-metastatic-non-small-cell-lung-cancer-nsclc
#7
Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, Jacqulyne P Robichaux, Hai Tran, Melissa K Shorter, Jadi M Bohac, Marcelo Vailati Negrao, Xiuning Le, Waree Rinsurogkawong, Jeff Lewis, Lara Lacerda, Emily B Roarty, Stephen G Swisher, Jack A Roth, Jianjun Zhang, Vassiliki Papadimitrakopoulou, John V Heymach
INTRODUCTION: Although most NSCLC patients with sensitizing epidermal growth factor receptor (EGFR) mutations have an impressive initial response, the vast majority has residual disease and develops acquired resistance after 9 to 14 months of EGFR tyrosine kinase (TKI) therapy. We recently reported a phase II trial showing that, for patients with molecularly unselected oligometastatic NSCLC who did not progress after first-line systemic therapy, local consolidation therapy (LCT) with surgery or radiation improved progression-free survival (PFS), compared with maintenance therapy alone...
September 24, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30341018/efficacy-of-local-consolidative-therapy-for-oligometastatic-lung-adenocarcinoma-patients-harboring-epidermal-growth-factor-receptor-mutations
#8
Fang Hu, Jianlin Xu, Bo Zhang, Changhui Li, Wei Nie, Ping Gu, Ping Hu, Huimin Wang, Yujun Zhang, Yinchen Shen, Shuyuan Wang, Xueyan Zhang
BACKGROUND: For oligometastatic lung adenocarcinoma patients with sensitive epidermal growth factor receptor (EGFR) mutations, the role of local consolidative therapy (LCT) remains debatable. The purpose of this study was to investigate the efficacy of LCT in oligometastatic lung adenocarcinoma patients. PATIENTS AND METHODS: We conducted a retrospective study to assess the effects of LCT on progression-free survival (PFS) and overall survival (OS). Patients with advanced-stage oligometastatic lung adenocarcinoma harboring sensitive mutation of epidermal growth factor receptor (EGFR) who received EGFR-tyrosine kinase inhibitor (TKI) or EGFR-TKI plus LCT were admitted to Shanghai Chest Hospital from January 2010 to December 2016...
September 24, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30341017/immune-microenvironment-differences-between-squamous-and-non-squamous-non-small-cell-lung-cancer-and-their-influence-on-the-prognosis
#9
Xiangjiao Meng, Yongsheng Gao, Lian Yang, Haiyan Jing, Feifei Teng, Zhaoqin Huang, Ligang Xing
INTRODUCTION: Checkpoint blockades have entered routine clinical use for non-small-cell lung cancer (NSCLC). However, there were some differences in efficacy and response predictors for anti-programmed cell death protein 1 (PD-1) antibodies between squamous (SQ) and nonsquamous (non-SQ) NSCLC. The study aims to elucidate the possible difference in immune microenvironment between SQ-NSCLC and non-SQ-NSCLC and their influence on the prognosis. PATIENTS AND METHODS: A total of 197 patients with stages I to III NSCLC were included...
September 24, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30337268/lymph-node-size-predicts-for-asymptomatic-brain-metastases-in-patients-with-non-small-cell-lung-cancer-at-diagnosis
#10
Stephanie R Rice, Jason K Molitoris, Melissa A L Vyfhuis, Martin J Edelman, Whitney M Burrows, Josephine Feliciano, Elizabeth M Nichols, Mohan Suntharalingam, James Donahue, Shamus R Carr, Joseph Friedberg, Shahed Badiyan, Charles B Simone, Steven J Feigenberg, Pranshu Mohindra
BACKGROUND: We questioned whether the National Comprehensive Cancer Network recommendations for brain magnetic resonance imaging (MRI) for patients with stage ≥ IB non-small-cell lung cancer (NSCLC) was high-yield compared with American College of Clinical Pharmacy and National Institute for Health and Care Excellence guidelines recommending stage III and above NSCLC. We present the prevalence and factors predictive of asymptomatic brain metastases at diagnosis in patients with NSCLC without extracranial metastases...
September 24, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30309777/adjuvant-therapy-in-patients-with-completely-resected-non-small-cell-lung-cancer-current-status-and-perspectives
#11
Robert Pirker, Martin Filipits
Patients with early-stage non-small-cell lung cancer undergo surgery with curative intent. Many of these patients relapse and, therefore, adjuvant therapies are important for improving survival of these patients. Adjuvant chemotherapy has been established and increases the 5-year survival rate. Here, we discuss systemic treatment strategies for further improving outcome of patients with completely resected non-small-cell lung cancer.
September 24, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30337270/efficacy-of-nivolumab-and-pembrolizumab-in-patients-with-advanced-non-small-cell-lung-cancer-needing-treatment-interruption-because-of-adverse-events-a-retrospective-multicenter-analysis
#12
Doran Ksienski, Elaine S Wai, Nicole Croteau, Leathia Fiorino, Edward Brooks, Zia Poonja, Dave Fenton, Georiga Geller, Daniel Glick, Mary Lesperance
INTRODUCTION: The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC). We evaluated the correlation between immune-related adverse events (irAE) and treatment interruption due to irAE on clinical efficacy of PD-1 Ab in advanced NSCLC. PATIENTS AND METHODS: Advanced NSCLC patients treated with PD-1 Ab between June 2015 to November 2017 at BC Cancer were identified. Demographic, tumor, treatment details, and frequency and grade (Common Terminology Criteria for Adverse Events, version 4...
September 22, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30366769/the-kif5b-ret-fusion-gene-mutation-as-a-novel-mechanism-of-acquired-egfr-tyrosine-kinase-inhibitor-resistance-in-lung-adenocarcinoma
#13
You-Cai Zhu, Wen-Xian Wang, Qu-Xia Zhang, Chun-Wei Xu, Wu Zhuang, Kai-Qi Du, Gang Chen, Tang-Feng Lv, Yong Song
No abstract text is available yet for this article.
September 21, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30341016/successful-treatment-of-a-patient-with-nsclc-harboring-an-egfr-mutation-and-a-concomitant-met-exon-14-skipping-mutation-combining-afatinib-and-crizotinib
#14
Diego Kauffmann-Guerrero, Kathrin Kahnert, Jörg Kumbrink, Zulfiya Syunyaeva, Amanda Tufman, Rudolf M Huber
No abstract text is available yet for this article.
September 21, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30327246/elective-nodal-irradiation-as-adjuvant-radiotherapy-for-advanced-thymomas-and-thymic-carcinomas
#15
Yeon Joo Kim, Su Ssan Kim, Si Yeol Song, Seung-Il Park, Dong Kwan Kim, Yong-Hee Kim, Hyeong Ryul Kim, Eun Kyung Choi
INTRODUCTION: We evaluated the clinical outcome of patients with stage III to IV thymomas (Ts) or stage II to IV thymic carcinomas (TCs) treated with complete thymectomy and local radiation therapy (LRT, targeting the tumor bed and anterior mediastinal areas only) or elective nodal irradiation (ENI, targeting the entire mediastinal and supraclavicular regions). MATERIALS AND METHODS: Data from 47 patients diagnosed with Ts or TCs and treated with surgery and adjuvant RT from May 2002 to May 2015 were analyzed...
September 21, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30318176/severe-acute-hepatitis-in-a-patient-receiving-alectinib-for-alk-positive-non-small-cell-lung-cancer-histologic-analysis
#16
Viola W Zhu, Yuxin Lu, Sai-Hong Ignatius Ou
No abstract text is available yet for this article.
September 21, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30337269/five-year-long-term-outcomes-of-stereotactic-body-radiation-therapy-for-operable-versus-medically-inoperable-stage-i-non-small-cell-lung-cancer-analysis-by-operability-fractionation-regimen-tumor-size-and-tumor-location
#17
Caitlin A Schonewolf, Marina Heskel, Abigail Doucette, Sunil Singhal, Melissa A Frick, Eric P Xanthopoulos, Michael N Corradetti, Joseph S Friedberg, Taine T Pechet, John P Christodouleas, William Levin, Abigail Berman, Keith A Cengel, Vivek Verma, Stephen M Hahn, John C Kucharczuk, Ramesh Rengan, Charles B Simone
BACKGROUND: Stereotactic body radiation therapy (SBRT) is standard for medically inoperable stage I non-small-cell lung cancer (NSCLC) and is emerging as a surgical alternative in operable patients. However, limited long-term outcomes data exist, particularly according to operability. We hypothesized long-term local control (LC) and cancer-specific survival (CSS) would not differ by fractionation schedule, tumor size or location, or operability status, but overall survival (OS) would be higher for operable patients...
September 20, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30348595/stereotactic-ablative-radiotherapy-as-an-alternative-to-lobectomy-in-patients-with-medically-operable-stage-i-nsclc-a-retrospective-multicenter-analysis
#18
Vieri Scotti, Alessio Bruni, Giulio Francolini, Marco Perna, Polina Vasilyeva, Mauro Loi, Gabriele Simontacchi, Domenico Viggiano, Biancaluisa Lanfranchi, Alessandro Gonfiotti, Juljana Topulli, Emanuela Olmetto, Virginia Maragna, Katia Ferrari, Viola Bonti, Camilla Comin, Sara Balduzzi, Roberto D'Amico, Frank Lohr, Luca Voltolini, Lorenzo Livi
BACKGROUND: Stereotactic ablative body radiation therapy (SBRT) has evolved as the standard treatment for patients with inoperable stage I non-small-cell lung cancer (NSCLC). We report the results of a retrospective analysis conducted on a large, well-controlled cohort of patients with stage I to II NSCLC who underwent lobectomy (LOB) or SBRT. MATERIALS AND METHODS: One hundred eighty-seven patients with clinical-stage T1a-T2bNoMO NSCLC were treated in 2 academic hospitals between August 2008 and May 2015...
September 8, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30279109/predictors-of-distant-failure-after-stereotactic-body-radiation-therapy-for-stages-i-to-iia-non-small-cell-lung-cancer
#19
Chelsea J Miller, Brendan Martin, Kyle Stang, Ryan Hutten, Fiori Alite, Christina Small, Bahman Emami, Matthew M Harkenrider
PURPOSE: The use of stereotactic body radiation therapy (SBRT) has emerged as an effective treatment modality for patients with early-stage non-small-cell lung cancer (NSCLC), with excellent local control rates. Despite this, there is a predominant pattern of distant failure. We sought to identify factors that help predict which patients with stages I to IIA NSCLC treated with SBRT are at highest risk of distant failure, so that we may utilize these factors in the future to help determine which patients may benefit from the addition of systemic therapies...
September 8, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30297175/preselection-of-lung-cancer-cases-using-fgfr1-mrna-and-gene-copy-number-for-treatment-with-ponatinib
#20
Terry L Ng, Hui Yu, Derek E Smith, Theresa A Boyle, Emily R York, Scott Leedy, Dexiang Gao, Dara L Aisner, Adrie Van Bokhoven, Lynn E Heasley, Fred R Hirsch, D Ross Camidge
INTRODUCTION: Preclinically, high epidermal growth factor receptor 1 (FGFR1) messenger RNA (FGFR1-MRNA) and FGFR1 amplification (FGFR1-AMP) predicted sensitivity to fibroblast growth factor receptor inhibitors in non-small-cell lung cancer and small-cell lung cancer cell lines. KRAS mutations did not preclude sensitivity. PATIENTS AND METHODS: Metastatic EGFR- and ALK-negative lung cancers were screened for FGFR1-MRNA by in-situ hybridization (ISH) and FGFR1-AMP by silver in-situ hybridization (SISH)...
September 7, 2018: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"